H
Ho Yeong Lim
Researcher at Samsung Medical Center
Publications - 346
Citations - 20084
Ho Yeong Lim is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Cancer & Hepatocellular carcinoma. The author has an hindex of 51, co-authored 312 publications receiving 13336 citations. Previous affiliations of Ho Yeong Lim include Samsung & Sungkyunkwan University.
Papers
More filters
Journal ArticleDOI
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed O Kaseb,Daneng Li,Wendy Verret,Derek-Zhen Xu,Sairy Hernandez,Juan Liu,Chen Huang,Sohail M. Mulla,Yulei Wang,Ho Yeong Lim,Andrew X. Zhu,Ann-Lii Cheng,IMbrave Investigators +21 more
TL;DR: In patients with unresectable hepatocellular carcinoma, atezolIZumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib.
Journal ArticleDOI
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X. Zhu,Yoon-Koo Kang,Chia Jui Yen,Richard S. Finn,Peter R. Galle,Josep M. Llovet,Josep M. Llovet,Eric Assenat,Giovanni Brandi,Marc Pracht,Ho Yeong Lim,Kun-Ming Rau,Kenta Motomura,Izumi Ohno,Philippe Merle,Bruno Daniele,Dong Bok Shin,Guido Gerken,Christophe Borg,Jean-Baptiste Hiriart,Takuji Okusaka,Manabu Morimoto,Yanzhi Hsu,Paolo Abada,Masatoshi Kudo +24 more
TL;DR: Overall survival, progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, and time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8) were significantly improved in the ramucirumab group compared with the placebo group.
Journal ArticleDOI
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn,Baek-Yeol Ryoo,Philippe Merle,Masatoshi Kudo,Mohamed Bouattour,Ho Yeong Lim,Valeriy Breder,Julien Edeline,Yee Chao,Sadahisa Ogasawara,Thomas Yau,Marcelo Garrido,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Scot Ebbinghaus,Erluo Chen,Abby B. Siegel,Andrew X. Zhu,Ann-Lii Cheng +19 more
TL;DR: The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population, and one-sided significance thresholds for OS and PFS did not reach statistical significance per specified criteria.
Journal ArticleDOI
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu,Manish A. Shah,Eric Van Cutsem,Sun Young Rha,Akira Sawaki,Sook Ryun Park,Ho Yeong Lim,Yasuhide Yamada,Jian Wu,B. Langer,Michal Starnawski,Yoon-Koo Kang +11 more
TL;DR: The Avastin in Gastric Cancer (AVAGAST) trial as discussed by the authors evaluated the efficacy of adding bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric cancer.
Journal ArticleDOI
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim,Razvan Cristescu,Adam J. Bass,Kyoung-Mee Kim,Justin I. Odegaard,Kyung Kim,Xiaoqiao Liu,Xinwei Sher,Hun Jung,Mijin Lee,Su Jin Lee,Se Hoon Park,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Hyuk Lee,Min-Gew Choi,Amir Ali Talasaz,Peter Soonmo Kang,Jonathan D. Cheng,Andrey Loboda,Jeeyun Lee,Won Ki Kang +22 more
TL;DR: Findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.